Literature DB >> 8523154

Safety of pneumococcal revaccination.

R Rodriguez1, P D Dyer.   

Abstract

Indications for pneumococcal polysaccharide revaccination include highest-risk patients vaccinated more than six years previously, but there is controversy regarding revaccination of patients with chronic medical conditions and revaccination of the elderly. The object of the study was to investigate whether revaccination with the pneumococcal polysaccharide vaccine would cause significant adverse reactions. 151 patients were revaccinated and completed a questionnaire concerning the 72 hours after the injection. Valid data were obtained from 127 patients. Mild systemic reactions varied from 4% to 8% and local reactions varied from 40% to 60%, which is not different from the reported reaction with the initial vaccination. This profile of adverse reactions after revaccination should minimize concerns about revaccination.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8523154     DOI: 10.1007/bf02602403

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  2 in total

1.  Pneumococcal vaccine: dose, revaccination, and coadministration with influenza vaccine.

Authors:  A J Carlson; W L Davidson; A A McLean; P P Vella; R E Weibel; A F Woodhour; M R Hilleman
Journal:  Proc Soc Exp Biol Med       Date:  1979-09

Review 2.  Pneumococcal polysaccharide vaccine.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1989-02-10       Impact factor: 17.586

  2 in total
  4 in total

1.  Pneumococcal vaccine.

Authors:  R A Pennie
Journal:  Can Fam Physician       Date:  1999-10       Impact factor: 3.275

2.  Severe febrile systemic reaction to pneumococcal vaccine.

Authors:  Syed Hasan; Mahmoud Yousef; Sachin Shridharani
Journal:  J Natl Med Assoc       Date:  2005-02       Impact factor: 1.798

3.  A brief history of pneumococcal vaccines.

Authors:  R Austrian
Journal:  Drugs Aging       Date:  1999       Impact factor: 3.923

4.  Revaccination of adults with spinal cord injury using the 23-valent pneumococcal polysaccharide vaccine.

Authors:  Ken B Waites; Kay C Canupp; Yu-Ying Chen; Michael J DeVivo; Moon H Nahm
Journal:  J Spinal Cord Med       Date:  2008       Impact factor: 1.985

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.